- Meets the American College of Rheumatology (ACR) 1987 revised criteria for
classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening
- Active RA at the time of screening and baseline consisting of >= 5 swollen and >= 5
tender joints (28-joint count) and at least 1 of the following at screening:
C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h
- Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (up
to 25 mg weekly) for at least 8 weeks prior to the baseline visit.
- Subjects with other rheumatic diseases
- Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamous
cell carcinoma or in situ cervical cancer)
- Any prior use of B cell-depleting therapy